-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor's note: l Adding atezolizumab to the FOLFOXIRI/bevacizumab regimen can prolong the progression-free survival of patients with metastatic colorectal cancer——LBA20—FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as fifirst-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO.
l For newly-treated EGFR-mutant non-squamous NSCLC patients, osimertinib is better than a single agent or a combination of benzal Valizumab is good? ——LBA44—primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study.
l How to optimize the ToGA program? Trastuzumab+nivolumab+FOLFOX further improves the overall survival rate of patients with esophageal gastric adenocarcinoma! ——LBA45—Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) – results of the randomized phase 2 INTEGA trial (AIO STO 0217).
l For newly-treated EGFR-mutant non-squamous NSCLC patients, osimertinib is better than a single agent or a combination of benzal Valizumab is good? ——LBA44—primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study.
l How to optimize the ToGA program? Trastuzumab+nivolumab+FOLFOX further improves the overall survival rate of patients with esophageal gastric adenocarcinoma! ——LBA45—Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) – results of the randomized phase 2 INTEGA trial (AIO STO 0217).
